EE403 Cost-Effectiveness Analysis of Nivolumab Compared to Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.651
https://www.valueinhealthjournal.com/article/S1098-3015(22)00852-X/fulltext
Title :
EE403 Cost-Effectiveness Analysis of Nivolumab Compared to Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00852-X&doi=10.1016/j.jval.2022.04.651
First page :
Section Title :
Open access? :
No
Section Order :
10585